Chronic Subdural Hematoma
Conditions
Interventions
treatment group:Boring drainage+Oral administration of adrenal chromizone tablets
control group:Boring drainage
Sponsors
Wuxi No. 2 People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following criteria to be eligible for enrollment: 1. Adult (18=age=80 years old, gender not limited; 2. Diagnosed with chronic subdural hematoma (CSDH) by CT/MRI; 3. Presence of CH-related symptoms including: headache, gait disturbance, confusion or decreased level of consciousness, limb weakness, speech disorder, drowsiness or decreased level of consciousness, regardless of severity of the symptoms; 4. Modified Rankin Scale (mRS) score =1 point before treatment; 5. Normal liver and kidney function: Alanineinotransferase (ALT) =2 times the upper limit of normal, Glomerular filtration rate (GFR) =60 ml/min; 6. Normal coagulation function: Platelet count =100×10?/L, International normalized ratio (INR) =1.2. 7. Patients or their agents are able to understand the purpose of the trial, voluntarily participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria will be excluded from this study: 1.Acute subdural hematoma with density on CT; 2. Combined with intracranial tumors and other intracranial space-occupying lesions; 3. History of intracranial hemorage, cerebral infarction, or major surgery within 30 days before treatment; 4. Active bleeding, coagulation dysfunction, or uncorrectable bleeding tendency 5. History of epilepsy, psychosis, etc., which limits the use of drugs; 6.Allergic to adrenalchrome, salicylic acid, its excipients; 7. Currently using antihistamines, anticholinergics, and other drugs that interact with adrenalchrome; 8. Severe heart liver, or kidney dysfunction, or other severe advanced diseases of other systems; 9. Expected survival time <1 year; 10. Pregnant women; 11. Participating in other clinical trials that have not yet ended, or have participated in similar studies in the past 3 months; 12. Those who refuse to cooperate or tolerate treatment; 13. Those who cannot complete the planned follow-up; 14. Investigators believe that there are other conditions that affect the safety of the study the reliability of the results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of chronic subdural hematoma; | — |
Secondary
| Measure | Time frame |
|---|---|
| neurological deficit status;activities of daily living; | — |
Countries
China
Contacts
Public ContactZhao xudong
Wuxi No. 2 People’s Hospital
Outcome results
None listed